Sara A. Hurvitz, MD | Authors

June 01, 2022

Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.

May 30, 2022

Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.

May 29, 2022

Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.

May 26, 2022

Sara Hurvitz, MD, spoke about to recent approval of fam-trastuzumab deruxtecan-nxki in the second-line setting for patients with HER2-positive breast cancer.

May 09, 2022

A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.

March 31, 2022

A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.

March 31, 2022

Improvements regarding the identification and management of radiation necrosis in patients with HER2-positive metastatic breast cancer.

March 24, 2022

The importance of forming partnerships with patients and understanding their preferences for therapy when establishing treatment algorithms for patients with HER2-positive metastatic breast cancer.

March 24, 2022

Sara A. Hurvitz, MD, and Julia A. LaBarbera, NP, of UCLA, highlight the safety and efficacy profiles of newer novel treatment options available for HER2-positive breast cancer and brain metastases.

March 17, 2022

Variables that impact decisions to treat HER2-positive breast cancer and brain metastases with radiation therapy and systemic therapy, and recommendations on using memantine following radiation therapy.